Authors: van Zuylen, L Sparreboom, A van der Gaast, A van der Burg, MEL van Beurden, V Bol, CJ Woestenborghs, R Palmer, PA Verweij, J

Citation: L. Van Zuylen et al., The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel, CLIN CANC R, 6(4), 2000, pp. 1365-1371

Authors: de Jonge, MJA Loos, WJ Gelderblom, H Planting, AST van der Burg, MEL Sparreboom, A Brouwer, E van Beurden, V Mantel, MA Doyle, E Hearn, S Ross, G Verweij, J

Citation: Mja. De Jonge et al., Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence-dependent hematologic side effects, J CL ONCOL, 18(10), 2000, pp. 2104-2115

Authors: Gerrits, CJH Schellens, JHM Burris, H Eckardt, JR Planting, AST van der Burg, MEL Rodriguez, GI Loos, WJ van Beurden, V Hudson, I Von Hoff, DD Verweij, J

Citation: Cjh. Gerrits et al., A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin), CLIN CANC R, 5(1), 1999, pp. 69-75

Authors: de Jonge, MJA Punt, CJA Gelderblom, AH Loos, WJ van Beurden, V Planting, AST van der Burg, MEL van Maanen, LWGM Dallaire, BK Verweij, J Wagener, T Sparreboom, A

Citation: Mja. De Jonge et al., Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors, J CL ONCOL, 17(7), 1999, pp. 2219-2226

Authors: Pronk, LC van Putten, WLJ van Beurden, V de Boer-Dennert, M Stoter, G Verweij, J

Citation: Lc. Pronk et al., The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative study, CANC CHEMOT, 43(2), 1999, pp. 173-177